Aytu BioPharma, Inc. (AYTU)
USD 1.31
(-1.88%)
USD 1.31
(-1.88%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 81 Million USD | -24.58% |
| 2023 | 107.39 Million USD | 11.1% |
| 2022 | 96.66 Million USD | 47.29% |
| 2021 | 65.63 Million USD | 137.52% |
| 2020 | 27.63 Million USD | 277.47% |
| 2019 | 7.32 Million USD | 100.01% |
| 2018 | 3.66 Million USD | 13.61% |
| 2017 | 3.22 Million USD | 25.72% |
| 2016 | 2.56 Million USD | 878.85% |
| 2015 | 261.78 Thousand USD | 344.23% |
| 2014 | 58.92 Thousand USD | 3267.37% |
| 2013 | 1750.00 USD | 0.0% |
| 2012 | 1750.00 USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 1750.00 USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 17.99 Million USD | -21.54% |
| 2024 Q1 | 22.09 Million USD | -28.09% |
| 2024 Q4 | 17.97 Million USD | -0.09% |
| 2024 Q2 | 22.93 Million USD | 3.78% |
| 2023 Q4 | 30.73 Million USD | 35.19% |
| 2023 Q3 | 22.73 Million USD | -13.49% |
| 2023 FY | 107.39 Million USD | 11.1% |
| 2023 Q1 | 27.65 Million USD | 0.75% |
| 2023 Q2 | 26.27 Million USD | -4.98% |
| 2022 Q3 | 24.19 Million USD | 4.64% |
| 2022 Q4 | 27.44 Million USD | 13.43% |
| 2022 FY | 96.66 Million USD | 47.29% |
| 2022 Q2 | 23.12 Million USD | 5.61% |
| 2022 Q1 | 21.89 Million USD | -6.75% |
| 2021 Q1 | 13.52 Million USD | -9.02% |
| 2021 Q4 | 23.48 Million USD | 74.17% |
| 2021 Q2 | 15.14 Million USD | 12.03% |
| 2021 Q3 | 13.48 Million USD | -10.99% |
| 2021 FY | 65.63 Million USD | 137.52% |
| 2020 Q4 | 14.86 Million USD | 82.2% |
| 2020 FY | 27.63 Million USD | 277.47% |
| 2020 Q3 | 8.15 Million USD | 156.87% |
| 2020 Q1 | 1.43 Million USD | -16.07% |
| 2020 Q2 | 3.17 Million USD | 120.53% |
| 2019 Q2 | 1.79 Million USD | 25.35% |
| 2019 Q1 | 1.43 Million USD | 54.81% |
| 2019 Q4 | 1.71 Million USD | -27.85% |
| 2019 FY | 7.32 Million USD | 100.01% |
| 2019 Q3 | 2.37 Million USD | 32.47% |
| 2018 Q1 | 1.07 Million USD | 28.73% |
| 2018 FY | 3.66 Million USD | 13.61% |
| 2018 Q4 | 925 Thousand USD | 52.39% |
| 2018 Q3 | 607 Thousand USD | -42.25% |
| 2018 Q2 | 1.05 Million USD | -2.32% |
| 2017 Q3 | 894 Thousand USD | 12.59% |
| 2017 Q2 | 794 Thousand USD | 13.75% |
| 2017 Q4 | 835.88 Thousand USD | -6.5% |
| 2017 FY | 3.22 Million USD | 25.72% |
| 2017 Q1 | 698 Thousand USD | -25.53% |
| 2016 Q3 | 668.42 Thousand USD | 42.39% |
| 2016 Q4 | 937.3 Thousand USD | 40.23% |
| 2016 Q1 | 487.38 Thousand USD | 167.74% |
| 2016 Q2 | 469.42 Thousand USD | -3.68% |
| 2016 FY | 2.56 Million USD | 878.85% |
| 2015 Q1 | 27.58 Thousand USD | 2658.3% |
| 2015 Q4 | 182.03 Thousand USD | 663.93% |
| 2015 Q3 | 23.82 Thousand USD | 0.0% |
| 2015 Q2 | 23.82 Thousand USD | -13.61% |
| 2015 FY | 261.78 Thousand USD | 344.23% |
| 2014 Q1 | -3500.00 USD | -300.0% |
| 2014 Q2 | - USD | 100.0% |
| 2014 Q4 | 1000.00 USD | -92.0% |
| 2014 Q3 | 12.5 Thousand USD | 0.0% |
| 2014 FY | 58.92 Thousand USD | 3267.37% |
| 2013 Q2 | - USD | -100.0% |
| 2013 FY | 1750.00 USD | 0.0% |
| 2013 Q4 | 1750.00 USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | 1750.00 USD | 0.0% |
| 2012 FY | 1750.00 USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q1 | -1750.00 USD | -200.0% |
| 2010 Q2 | - USD | 100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | 1750.00 USD | 0.0% |
| 2009 Q4 | 1750.00 USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 1750.00 USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | 30.371% |
| Theratechnologies Inc. | 81.76 Million USD | 0.932% |
| Safety Shot Inc | 202.67 Thousand USD | -39867.435% |
| Cosmos Health Inc. | 53.37 Million USD | -51.755% |
| Cronos Group Inc. | 88.84 Million USD | 8.824% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 81.704% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 81.299% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -150.712% |
| ProPhase Labs, Inc. | 44.38 Million USD | -82.503% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -536.058% |
| Dynavax Technologies Corporation | 232.28 Million USD | 65.128% |
| Radius Health, Inc. | 2.88 Billion USD | 97.19% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -4100.266% |
| Alvotech | 91.43 Million USD | 11.409% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -236.209% |
| Alpha Teknova, Inc. | 36.68 Million USD | -120.81% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 82.557% |
| SCYNEXIS, Inc. | 140.14 Million USD | 42.2% |
| Harrow Health, Inc. | 130.19 Million USD | 37.783% |
| Biofrontera Inc. | 34.07 Million USD | -137.745% |
| DURECT Corporation | 8.54 Million USD | -847.613% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 86.667% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 83.361% |
| OptiNose, Inc. | 70.98 Million USD | -14.108% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1143.664% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -60.137% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -104.796% |
| SIGA Technologies, Inc. | 139.91 Million USD | 42.107% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 36.846% |
| Shineco, Inc. | 9.8 Million USD | -726.395% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 92.041% |
| Procaps Group S.A. | 409.92 Million USD | 80.24% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6121.352% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 99.475% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -236.209% |
| Rockwell Medical, Inc. | 83.61 Million USD | 3.122% |
| Incannex Healthcare Limited | 12 Thousand USD | -674916.667% |
| Tilray Brands, Inc. | 788.94 Million USD | 89.733% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 85.708% |
| PetIQ, Inc. | 1.1 Billion USD | 92.649% |
| Silver Spike Investment Corp. | 11.72 Million USD | -591.018% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.708% |
| Journey Medical Corporation | 79.18 Million USD | -2.3% |
| Alimera Sciences, Inc. | 80.75 Million USD | -0.307% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -1291.216% |
| Assertio Holdings, Inc. | 152.06 Million USD | 46.733% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | 92.773% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7425.234% |
| Procaps Group, S.A. | 409.92 Million USD | 80.24% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -189.676% |
| Hempacco Co., Inc. | 4.04 Million USD | -1902.206% |
| Talphera, Inc. | 651 Thousand USD | -12342.704% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 87.999% |
| Alvotech | 91.43 Million USD | 11.409% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 93.752% |
| Kamada Ltd. | 144.75 Million USD | 44.043% |
| Indivior PLC | 1.09 Billion USD | 92.589% |
| Currenc Group, Inc. | 53.25 Million USD | -52.101% |
| Evoke Pharma, Inc. | 5.18 Million USD | -1463.555% |
| Flora Growth Corp. | 76.07 Million USD | -6.482% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7425.234% |
| Evolus, Inc. | 202.08 Million USD | 59.917% |
| HUTCHMED (China) Limited | 837.99 Million USD | 90.334% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 87.43% |
| Akanda Corp. | 2.16 Million USD | -3650.002% |